Family · Pharmaceutical analytical standards
Dabrafenib
An inhibitor of the mutated BRAF protein, approved in the United States in 2013 for advanced melanoma with the BRAF V600E mutation and later extended to other tumours with the same alteration. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?Because the tumour learns to get round it within a few months, since 2014 it has been used together with trametinib, which blocks the MEK protein just downstream of BRAF: a double block on the same signalling pathway.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
